CoV Biotechnology is a startup, most recent round Acquired.
CoV Biotechnology is a startup. CoV Biotechnology has been acquired.
CoV Biotechnology develops booster vaccines and therapeutics effective against SARS-2 beta coronavirus variants, including a pan-sarbecovirus vaccine to protect against future variants and zoonotic crossovers.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.